/Biogen%20Inc%20logo%20on%20HQ-by%20Tada%20Images%20via%20Shutterstock.jpg)
With a market cap of $21.8 billion, Biogen Inc. (BIIB) is a global biotechnology leader specializing in therapies for neurological and neurodegenerative diseases. Its portfolio includes multiple sclerosis treatments such as Tecfidera, Vumerity, Avonex, Plegridy, and Tysabri, as well as Spinraza for spinal muscular atrophy and several biosimilars.
Companies valued at $10 billion or more are generally classified as “large-cap” stocks, and Biogen fits this criterion perfectly. Through strategic collaborations and continued innovation, Biogen is advancing treatments in Alzheimer’s disease, neuromuscular disorders, movement disorders, and beyond.
